Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia

Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia

IntroductionDespite the improvement in survival in acute lymphoblastic leukemia (ALL), there are still cases with evasion of chemotherapy-induced apoptosis. The IKK/NF-κB signaling pathway contributes to antiapoptotic gene expression. Pentoxifylline (PTX) inhibits IkB phosphorylation, blocking NF-κB...

Full description

Saved in:
Bibliographic Details
Main Authors: Violeta Salceda-Rivera, Pablo C. Ortiz-Lazareno, Georgina Hernández-Flores, Jorge R. Vazquez-Urrutia, Jesus Meza-Arroyo, Monzerrat Pardo-Zepeda, Hugo Romo-Rubio, Cesar Barba-Barba, Fernando Sánchez-Zubieta, Carlos Alfredo Barrón-Gallardo, Oscar Gonzalez-Ramella, Alejandro Bravo-Cuellar
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
MRD
ALL
clinical trials
apoptosis
Pentoxifylline
early remission
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1401262/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionDespite the improvement in survival in acute lymphoblastic leukemia (ALL), there are still cases with evasion of chemotherapy-induced apoptosis. The IKK/NF-κB signaling pathway contributes to antiapoptotic gene expression. Pentoxifylline (PTX) inhibits IkB phosphorylation, blocking NF-κB and antiapoptotic activity. MethodsWe conducted a randomized, double-blind clinical trial on pediatric ALL patients undergoing induction therapy, assigning them to PTX or placebo group. Bone marrow aspirates were obtained on days 1, 8, 15, and 22. Apoptosis was assessed using Annexin-V/propidium iodide. ResultsResults indicated that the PTX group exhibited higher apoptosis on day-8 (41.3% vs. 19.4%, p =0.029) and day-15 (35.0% vs. 14.2%, p <0.01). On day-8, the PTX group displayed an MRD of 0.25% vs. 18.2% (p <0.01) in placebo group; on day-15, the PTX group demonstrated an MRD of 0.09% vs. 1.4% (p =0.02). Patients achieving an MRD <0.01% on day-8 demonstrated a 3-year Overall Survival (OS) of 81.6% vs. 58.3% (p =0.03); on day-15, patients with MRD <0.01% had a 3-year OS of 77.9% vs. 54.5% (p =0.03). The PTX group achieved an MRD of <0.01% earlier on days-8 and 15, along with a higher apoptosis rate, indicating a more favorable therapeutic response. In the entire cohort, patients achieving MRD <0.01% on day-8 or 15 displayed superior OS. ConclusionOur study demonstrates that PTX enhances apoptosis and reduces MRD in pediatric acute lymphoblastic leukemia patients.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT02451774.
ISSN:2234-943X

Similar Items